大行评级｜建银国际：上调信达生物目标价至125港元 评级“跑赢大市”

Core Viewpoint - Jianyin International has upgraded the rating of Innovent Biologics to "Outperform" with a target price increase from HKD 110 to HKD 125, citing strong financial performance and product growth as key factors [1] Financial Performance - The company reported a profit of HKD 1.2 billion in the first half of the year, exceeding expectations [1] - Product revenue increased by 37% year-on-year to HKD 5.2 billion [1] Product Development - The launch of Mazdutide and the clinical progress of IBI-363 and IBI-3001 are seen as catalysts for growth [1] - The company's leading position in the Chinese biopharmaceutical sector is further solidified [1]